Why TPS Expands Your Clinical Reach
Subcortical Access
Where rTMS excels at cortical modulation, TPS delivers focused acoustic pulses capable of reaching deeper brain structures—hippocampus, thalamus, basal ganglia—targets previously inaccessible to non-invasive stimulation. This opens therapeutic pathways for neurodegenerative conditions, treatment-resistant presentations, and complex cases where cortical intervention alone proves insufficient.
Distinct Mechanism of Action
TPS operates through mechanical rather than electromagnetic stimulation. Focused ultrasound pulses create precisely targeted mechanotransduction effects, influencing neuroplasticity through pathways complementary to—not duplicative of—rTMS and tDCS. This enables multimodal treatment strategies within a single ecosystem.
Neuronavigation-Guided Precision
TPS integrates with advanced neuronavigation systems, enabling millimetre-accurate targeting of specific brain regions identified through NeuroMap® analysis. QPAN® translates qEEG findings into precise coordinate targets, ensuring every pulse reaches its intended destination with reproducible accuracy.
The Clinical Framework
QPAN® Protocol Integration
NeuroMap® analysis identifies not only cortical dysregulation patterns but also signatures suggesting subcortical involvement—connectivity disruptions, network inefficiencies, and biomarkers associated with deeper structural engagement. QPAN® evaluates these findings against TPS indication criteria, generating protocols that specify target coordinates, pulse parameters, session frequency, and treatment duration.
Complementary or Standalone Deployment
TPS protocols may be deployed as standalone interventions for appropriate presentations, or integrated within multimodal treatment plans combining cortical rTMS with subcortical TPS targeting. QPAN® orchestrates sequencing, ensuring complementary rather than competing effects across modalities.
Conditions Particularly Suited to TPS
- Alzheimer's disease and mild cognitive impairment — Learn more
- Neurodegenerative conditions with subcortical involvement
- Treatment-resistant depression with deep network dysregulation — Learn more
- Parkinson's disease motor and non-motor symptoms — Learn more
- Complex presentations requiring multimodal neuromodulation strategies
Operational Excellence
Standardised Clinical Method
Every TPS deployment follows reproducible protocols—from qEEG acquisition through EdfCheck™ validation, NeuroMap® analysis identifying subcortical targets, QPAN® protocol generation with precise coordinates, to treatment delivery with neuronavigation guidance. Same rigour, same auditability, same medico-legal defensibility as rTMS programmes.
Outcome Quantification
Follow-up qEEG assessments track neurophysiological changes. NeuroMap® quantifies improvements in connectivity patterns and network efficiency. The Digital Twin updates with accumulated evidence, enabling objective demonstration of therapeutic efficacy for commissioners, families, and regulatory bodies.
What to Expect
TPS treatment involves a comprehensive assessment process beginning with QEEG brain mapping to identify subcortical targets. Treatment sessions are delivered using neuronavigation guidance to ensure precise targeting. The number of sessions and treatment duration will be discussed during your consultation based on your specific condition and response.
Explore TPS Treatment
If you or a loved one is dealing with a neurodegenerative condition or treatment-resistant presentation, TPS may offer a new therapeutic pathway. Contact us to discuss whether TPS treatment could be appropriate.